Evidence map›Paper›PMID 38287501›Full record

ArticleThe Korean journal of internal medicine2024

Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study.

Ho-Young Yhim, Yong Park, Jeong-A Kim, Ho-Jin Shin, Young Rok Do, Joon Ho Moon, Min Kyoung Kim, Won Sik Lee, Dae Sik Kim, Myung-Won Lee and 8 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ho-Young YhimDepartment of Internal Medicine, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea.
Yong ParkDepartment of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
Jeong-A KimDepartment of Internal Medicine, The Catholic University of Korea, St. Vincent Hospital, Suwon, Korea.
Ho-Jin ShinDepartment of Internal Medicine, Pusan National University Hospital, Busan, Korea.
Young Rok DoDepartment of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.
Joon Ho MoonDepartment of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.
Min Kyoung KimDepartment of Internal Medicine, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Korea.
Won Sik LeeDepartment of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea.
Dae Sik KimDepartment of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
Myung-Won LeeDepartment of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Yoon Seok ChoiDepartment of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Seong Hyun JeongDepartment of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.
Kyoung Ha KimDepartment of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea.
Jinhang KimDepartment of Internal Medicine, The Catholic University of Korea, St. Vincent Hospital, Suwon, Korea.
Chang-Hoon LeeDepartment of Internal Medicine, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea.
Ga-Young SongDepartment of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea.
Deok-Hwan YangDepartment of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea.
Jae-Yong KwakDepartment of Internal Medicine, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea.

Funding

Biomedical Research Institute, Jeonbuk National University HospitalChonnam National University Hwasun Hospital Research Institute of Clinical Medicine HCRI22009Korea Health Industry Development InstituteMinistry of Health and Welfare HR20C0021
6 · The paper itself

Abstract

BACKGROUND/

aimsOptimal risk stratification based on simplified geriatric assessment to predict treatment-related toxicity and survival needs to be clarified in older patients with diffuse large B-cell lymphoma (DLBCL).

methodsThis multicenter prospective cohort study enrolled newly diagnosed patients with DLBCL (≥ 65 yr) between September 2015 and April 2018. A simplified geriatric assessment was performed at baseline using Activities of Daily Living (ADL), Instrumental ADL (IADL), and Charlson's Comorbidity Index (CCI). The primary endpoint was event-free survival (EFS).

resultsThe study included 249 patients, the median age was 74 years (range, 65-88), and 125 (50.2%) were female. In multivariable Cox analysis, ADL, IADL, CCI, and age were independent factors for EFS; an integrated geriatric score was derived and the patients stratified into three geriatric categories: fit (n = 162, 65.1%), intermediate-fit (n = 25, 10.0%), and frail (n = 62, 24.9%). The established geriatric model was significantly associated with EFS (fit vs. intermediate-fit, HR 2.61, p < 0.001; fit vs. frail, HR 4.61, p < 0.001) and outperformed each covariate alone or in combination. In 87 intermediate-fit or frail patients, the relative doxorubicin dose intensity (RDDI) ≥ 62.4% was significantly associated with worse EFS (HR, 2.15, 95% CI 1.30-3.53, p = 0.002). It was related with a higher incidence of grade ≥ 3 symptomatic non-hematologic toxicities (63.2% vs. 27.8%, p < 0.001) and earlier treatment discontinuation (34.5% vs. 8.0%, p < 0.001) in patients with RDDI ≥ 62.4% than in those with RDDI < 62.4%.

conclusionThis model integrating simplified geriatric assessment can risk-stratify older patients with DLBCL and identify those who are highly vulnerable to standard dose-intensity chemoimmunotherapy.

Indexed as

Geriatric AssessmentLymphoma, Large B-Cell, DiffuseActivities of Daily LivingAgedAged, 80 and overAge FactorsAntineoplastic Combined Chemotherapy ProtocolsComorbidityDecision Support TechniquesDoxorubicinFemaleFrail ElderlyFrailtyHumansMalePredictive Value of TestsDoxorubicinDiffuse large B-cell lymphomaDose intensityPrognosisSimplified geriatric assessmentToxicity

Identifiers

PMID38287501
PMCPMC11076889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.